Litcius/Paper detail

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

John A. Spertus, Jennifer Fine, Perry Elliott, Carolyn Y. Ho, Iacopo Olivotto, Sara Saberi, Wanying Li, Chantal Dolan, Matthew Reaney, Amy J. Sehnert, Daniel Jacoby

2021The Lancet215 citationsDOI

Topics & Concepts

MedicinePlaceboInternal medicineHypertrophic cardiomyopathyQuality of life (healthcare)CardiomyopathyRandomized controlled trialPhysical therapyClinical trialClinical endpointHeart failureNursingAlternative medicinePathologyCardiomyopathy and Myosin StudiesCardiovascular Function and Risk FactorsCardiovascular Conditions and Treatments
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Litcius